Medicamen Organics Limited — Updates, 18-11-2024: Press Release

Medicamen Organics Limited has reported a 49% increase in total revenue for the first half of FY25, reaching ₹1,685.66 crore compared to ₹1,132 crore in H1 FY24. EBITDA rose 15.39% to ₹277.44 crore, while PAT increased by 10.88% to ₹151.07 crore, reflecting growing demand for their products and effective operational strategies. The company is optimistic about its future prospects, emphasizing its low debt and strong financial position, alongside a commitment to developing new products.

On the operational front, Medicamen has signed a MoU with Depot Pharmacy Yego Limited to enhance its presence in East Africa and partnered with Mistycube Analytics to form Grande Etoile Pharmaceuticals Ltd, aiming to capture the French West African market. Medicamen will hold a 51% stake in this new entity, with an authorized capital of ₹5 crore, highlighting their strategy for growth in international markets.